Clinical Trials
2 trialsNCT02139592 2020-07-13
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Takeda
Completed
NCT03440788 2019-10-28
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
Multinational Center for Quality of Life Research, Russia
Unknown